LLY

1,107.71

+2.69%↑

JNJ

206.42

+0.38%↑

ABBV

231.6

-0.03%↓

UNH

327.54

+1.71%↑

AZN

93.02

+0.81%↑

LLY

1,107.71

+2.69%↑

JNJ

206.42

+0.38%↑

ABBV

231.6

-0.03%↓

UNH

327.54

+1.71%↑

AZN

93.02

+0.81%↑

LLY

1,107.71

+2.69%↑

JNJ

206.42

+0.38%↑

ABBV

231.6

-0.03%↓

UNH

327.54

+1.71%↑

AZN

93.02

+0.81%↑

LLY

1,107.71

+2.69%↑

JNJ

206.42

+0.38%↑

ABBV

231.6

-0.03%↓

UNH

327.54

+1.71%↑

AZN

93.02

+0.81%↑

LLY

1,107.71

+2.69%↑

JNJ

206.42

+0.38%↑

ABBV

231.6

-0.03%↓

UNH

327.54

+1.71%↑

AZN

93.02

+0.81%↑

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

108.33 1.88

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

106.67

Максимум

109.46

Ключови измерители
By Trading Economics
Приходи	-6.3M -53M
Продажби	2.8M 51M
EPS	-0.82
Марж на печалбата	-103.131
Служители	283
EBITDA	-7.6M -48M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+17.68% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-442M 7.1B
Предишно отваряне	106.45
Предишно затваряне	108.33

Настроения в новините

By Acuity

58%

42%

323 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.11.2025 г., 16:56 ч. UTC

Печалби

Значими двигатели на пазара

Alimentation Couche-Tard Shares Rise as 2Q Same-Store Sales Support Profit Growth

25.11.2025 г., 23:47 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

25.11.2025 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise After Stock Gains on Wall Street -- Market Talk

25.11.2025 г., 22:39 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

25.11.2025 г., 22:39 ч. UTC

Пазарно говорене

Vault Accelerates Exposure to Spot Gold Prices by Six Months -- Market Talk

25.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

25.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

25.11.2025 г., 21:38 ч. UTC

Печалби

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25.11.2025 г., 21:31 ч. UTC

Пазарно говорене

F&P Healthcare's Share Price Jumps on Profit Guidance Upgrade -- Market Talk

25.11.2025 г., 21:27 ч. UTC

Печалби

These Stocks Moved the Most Today: Nvidia, AMD, Alphabet, Abercrombie, Kohl's, Novo Nordisk, Symbotic, and More -- Barrons.com

25.11.2025 г., 21:20 ч. UTC

Печалби

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25.11.2025 г., 21:18 ч. UTC

Печалби

NIO Stock Drops as EV Maker Posts Narrower Loss -- Barrons.com

25.11.2025 г., 21:15 ч. UTC

Печалби

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25.11.2025 г., 20:16 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls as December Contract Expires -- Market Talk

25.11.2025 г., 18:42 ч. UTC

Пазарно говорене

USDA Backs Mexican Retail Expo to Raise Agricultural Exports -- Market Talk

25.11.2025 г., 18:25 ч. UTC

Придобивния, сливания и поглъщания

S&P Global Completes $1.8 Billion Acquisition Of With Intelligence, Strengthening Its Position As A Leader In Private Markets Data & Analytics >SPGI

25.11.2025 г., 17:30 ч. UTC

Пазарно говорене

Mexico Posts Record Foreign Direct Investment for Jan-Sep -- Market Talk

25.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

25.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

25.11.2025 г., 16:33 ч. UTC

Придобивния, сливания и поглъщания

Eni: Financial Details Weren't Disclosed

25.11.2025 г., 16:33 ч. UTC

Придобивния, сливания и поглъщания

Eni: Block OFF-5 Covers an Area of About 17,000 Km Sq. in Water Depths

25.11.2025 г., 16:32 ч. UTC

Придобивния, сливания и поглъщания

Eni: Agreement to Become Effective After Approval of Uruguayan Authorities

25.11.2025 г., 16:31 ч. UTC

Придобивния, сливания и поглъщания

Eni: Acquisition Is for a 50% Share, Operatorship in Exploration Block OFF-5

25.11.2025 г., 16:30 ч. UTC

Придобивния, сливания и поглъщания

Eni Acquires From YPF Shares in the Exploration Block OFF-5 Offshore Uruguay

25.11.2025 г., 16:23 ч. UTC

Печалби

This Robotics Stock Soars 40% on Earnings. Here's Why. -- Barrons.com

25.11.2025 г., 16:12 ч. UTC

Пазарно говорене

Euro Expected to Rise to $1.25 in 2026: Deutsche Bank -- Market Talk

25.11.2025 г., 16:11 ч. UTC

Пазарно говорене

Dollar Could Take One Final Leg Lower in Early 2026 -- Market Talk

25.11.2025 г., 16:10 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

25.11.2025 г., 16:10 ч. UTC

Пазарно говорене

Sterling Could Briefly Rise After Budget -- Market Talk

25.11.2025 г., 16:10 ч. UTC

Пазарно говорене

Oil Extends Losses on Ukraine-Russia Peace Deal Hopes -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

17.68% нагоре

12-месечна прогноза

Среден 125.42 USD 17.68%

Висок 142 USD

Нисък 110 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

323 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.